CARDIOVASCULAR BENEFITS OF SOY PHYTOESTROGENS
大豆植物雌激素对心血管的益处
基本信息
- 批准号:6389158
- 负责人:
- 金额:$ 212.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-01-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROPOSED PROGRAM: (Adapted from Applicant's Abstract) This PPG continues to be a group of interrelated projects focused primarily on the potential cardiovascular benefits of soy phytoestrogen supplementation/treatment. Potential benefits of soy phytoestrogens (SPEs) for breast and uterus of females and of prostate of males constitute a secondary focus. The research is directed toward males and pre and postmenopausal females. In Project 1, the investigators will intensify their pharmacologic studies of the soy phytoestrogens (SPEs) by addressing four questions: 1. What is the peptide fraction of soy protein that is required for the phytoestrogens (isoflavones) to have their effect on lipid metabolism? 2. Are there differences in the effects of soy phytoestrogen preparations that are predominately genistein or predominately daidzein? 3. What is the relationship between dose of soy phytoestrogens and their metabolic effects? 4. What are the longer term effects of the "optimal" soy treatment? The major objective of Project 2 is to assess the usefulness of soy phytoestrogens in primary cardioprotection of adult male monkeys. Also, the study will address directly whether long-term soy consumption is without adverse effects on the reproductive system, cognition, social and sexual behavior and function and determine if it has favorable effects on the prostate gland. Postmortem assessments will be made of atherosclerosis extent and arterial expression of estrogen receptors (alpha and beta). In addition, immunohistochemical and histomorphometric markers of prostatic hyperplasia and neoplasia will be studied as will histomorphometric markers of mammary gland hyperplasia and neoplasia. Project 3 is a comprehensive, periclinical study that will determine whether treatment with SPEs inhibits the progression of coronary and carotid artery atherosclerosis and improves coronary artery dilator responses in high risk, subordinate premenopausal monkeys. Furthermore, the study will determine whether SPEs inhibit or potentiate proliferation and estrogenic responses in the endometrium and mammary tissue of premenopausal monkeys, and whether SPEs adversely affect or improve bone development and peak bone mass in these females.
拟议预算:(改编自申请人的摘要)该PPG仍然是一组相互关联的项目,主要集中在大豆植物雌激素补充/治疗的潜在心血管益处上。 大豆植物雌激素(SPE)对女性乳腺和子宫以及男性前列腺的潜在益处构成了次要焦点。 这项研究是针对男性和绝经前后的女性。 在项目1中,研究人员将通过解决以下四个问题来加强对大豆植物雌激素(SPE)的药理学研究:1。 植物雌激素(雌激素)对脂质代谢产生影响所需的大豆蛋白的肽部分是什么?2. 以染料木黄酮或大豆苷元为主的大豆植物雌激素制剂的作用是否存在差异? 3. 大豆植物雌激素的剂量与其代谢效应之间的关系是什么? 4. “最佳”大豆处理的长期效果是什么? 项目2的主要目的是评估大豆植物雌激素在成年雄性猴的初级心脏保护中的有用性。 此外,该研究将直接解决长期食用大豆是否对生殖系统,认知,社会和性行为和功能没有不利影响,并确定它是否对前列腺有有利影响。 将对动脉粥样硬化程度和雌激素受体(α和β)的动脉表达进行尸检评估。 此外,还将研究前列腺增生和肿瘤的免疫组织化学和组织形态计量学标志物,以及乳腺增生和肿瘤的组织形态计量学标志物。 项目3是一项综合性的临床前研究,将确定SPE治疗是否抑制冠状动脉和颈动脉粥样硬化的进展,并改善高风险、从属绝经前猴的冠状动脉扩张反应。 此外,该研究将确定SPE是否抑制或增强绝经前猴子宫内膜和乳腺组织的增殖和雌激素反应,以及SPE是否对这些雌性动物的骨发育和峰值骨量产生不利影响或改善。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS B CLARKSON其他文献
THOMAS B CLARKSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS B CLARKSON', 18)}}的其他基金
Depressive Symptoms and Cognitive Complaints in the Menopausal Transition: Scient
更年期过渡期的抑郁症状和认知障碍:科学
- 批准号:
7752138 - 财政年份:2009
- 资助金额:
$ 212.94万 - 项目类别:
DEVELOPING AND IMPROVING INSTITUTIONAL ANIMAL RESOURCES
开发和改善机构动物资源
- 批准号:
3059226 - 财政年份:1991
- 资助金额:
$ 212.94万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 212.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
- 批准号:
10974007 - 财政年份:2023
- 资助金额:
$ 212.94万 - 项目类别:














{{item.name}}会员




